Renee Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Renee Chen has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ariana Aghevli
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota
1 shared publication - Biyun Ji
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota
1 shared publication - Chuan Chen
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota
1 shared publication - Jinghua Hu
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA
1 shared publication - Kai He
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota
1 shared publication - Kun Ling
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota
1 shared publication
Latest Publications
- 14 September 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
CDK4/6 Inhibitor Abemaciclib Arrests and Reverses Kidney Cyst Progression in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease
Key Points: CDK6 was robustly upregulated in cyst-lining epithelial cells. The CDK4/6 inhibitor abemaciclib restored axonemal polyglutamylation and increased ciliary polycystin dosage in autosomal dominant polycystic kidney disease renal epithelial cells. Abemaciclib arrested or reversed cyst progression in a sex-specific manner with greater efficacy and safety than tolvaptan in an autosomal dominant polycystic kidney disease mouse model. Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited disorder leading to kidney failure. Tolvaptan, the only US Food and Drug Administration–approved therapy, modestly slows disease progression but is limited by significant adverse effects, highlighting the need for more effective and better-tolerated treatments. Ciliary polycystins are central to ADPKD pathogenesis. We previously demonstrated that a ciliary base–localized pool of CDK6 restricts ciliary polycystin abundance by suppressing axonemal polyglutamylation. However, whether CDK6 inhibition can restore polycystin function and suppress ADPKD progression in vivo remains unknown. Methods: Abemaciclib was tested in in vitro 3D cyst assays and ex vivo metanephric organ cultures. In vivo efficacies of early- and late-stage intervention were assessed in F1(129/B6) Pkd1 R3277C/R3277C mice receiving daily abemaciclib. Tolvaptan served as a therapeutic control. Cyst burden, fibrosis in the kidneys, kidney function, and primary cilia of renal epithelial cells were analyzed at study end points. Results: CDK6 was prominently upregulated in cyst-lining cells in human and murine polycystic kidney disease kidneys. At doses substantially lower than those used in oncology, abemaciclib robustly suppressed cyst growth in vitro and ex vivo . In vivo , long-term early treatment arrested cyst progression more effectively than tolvaptan without detectable toxicity. Late intervention largely halted cyst growth in female mice and reversed cyst progression in male mice. Mechanistically, abemaciclib restored axonemal polyglutamylation and increased ciliary polycystin levels. Conclusions: Abemaciclib had greater therapeutic efficacy and tolerability than tolvaptan in this preclinical model, largely driven by CDK6 inhibition–mediated restoration of axonemal polyglutamylation and increased ciliary polycystin abundance.
- 14 September 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
CDK4/6 Inhibitor Abemaciclib Arrests and Reverses Kidney Cyst Progression in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease
Key Points: CDK6 was robustly upregulated in cyst-lining epithelial cells. The CDK4/6 inhibitor abemaciclib restored axonemal polyglutamylation and increased ciliary polycystin dosage in autosomal dominant polycystic kidney disease renal epithelial cells. Abemaciclib arrested or reversed cyst progression in a sex-specific manner with greater efficacy and safety than tolvaptan in an autosomal dominant polycystic kidney disease mouse model. Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited disorder leading to kidney failure. Tolvaptan, the only US Food and Drug Administration–approved therapy, modestly slows disease progression but is limited by significant adverse effects, highlighting the need for more effective and better-tolerated treatments. Ciliary polycystins are central to ADPKD pathogenesis. We previously demonstrated that a ciliary base–localized pool of CDK6 restricts ciliary polycystin abundance by suppressing axonemal polyglutamylation. However, whether CDK6 inhibition can restore polycystin function and suppress ADPKD progression in vivo remains unknown. Methods: Abemaciclib was tested in in vitro 3D cyst assays and ex vivo metanephric organ cultures. In vivo efficacies of early- and late-stage intervention were assessed in F1(129/B6) Pkd1 R3277C/R3277C mice receiving daily abemaciclib. Tolvaptan served as a therapeutic control. Cyst burden, fibrosis in the kidneys, kidney function, and primary cilia of renal epithelial cells were analyzed at study end points. Results: CDK6 was prominently upregulated in cyst-lining cells in human and murine polycystic kidney disease kidneys. At doses substantially lower than those used in oncology, abemaciclib robustly suppressed cyst growth in vitro and ex vivo . In vivo , long-term early treatment arrested cyst progression more effectively than tolvaptan without detectable toxicity. Late intervention largely halted cyst growth in female mice and reversed cyst progression in male mice. Mechanistically, abemaciclib restored axonemal polyglutamylation and increased ciliary polycystin levels. Conclusions: Abemaciclib had greater therapeutic efficacy and tolerability than tolvaptan in this preclinical model, largely driven by CDK6 inhibition–mediated restoration of axonemal polyglutamylation and increased ciliary polycystin abundance.